With a strong background in research and development, HempFusion is at the forefront of health and wellness in the rapidly growing CBD industry. The company distributes its family of brands to approximately 4,000 retailers across 47 US states, with plans for further international expansion.

HempFusion is focused on providing innovative and diverse proprietary formulation using the power of whole-food hemp nutrition and marketing premium consumer-specific product lines across multiple distribution platforms. HempFusion is now expanding its distribution beyond its natural and e-commerce channels into doctor and practitioner networks, convenience and food-drug mass and big box retailers.


HempFusion is one of the few companies marketing FDA Drug Listed Topicals in compliance with all FDA regulations. Understanding the uncertainties of an emerging industry like CBD, HempFusion is working with twelve other CBD companies to conduct a study addressing FDA concerns regarding CBD products and human safety.

HempFusion Wellness Company Highlights

  • Premium wellness company focused on providing innovative and diversified proprietary formulation using the power of whole-food hemp.
  • Armed with world-class research and developmental processes, the company is prepared to market its premium CBD product lines across multiple distribution platforms.
  • Offers a wide variety of CBD products that contain a broad spectrum of panoramic hemp extract, including liquids/tinctures, capsules, travel pouches and OTC topical products.
  • Key partnerships with Verdant Oasis and Probulin Probiotics Co. has strategically positioned the company for international expansion into European markets and medicinal distribution networks.
  • As of June 2020, HempFusion Wellness holds the second-largest cash position in the CBD sector, with over $18.3 million in cash and an estimated 1,750 shareholders.
  • Plans to launch on the Toronto Stock Exchange senior board as they continue to grow.

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less